Biogen Stock Pops After FDA Approves Drug For Spinal Muscular Atrophy - Biogen (NASDAQ:BIIB)

Biogen Stock Pops After FDA Approves Drug For Spinal Muscular Atrophy - Biogen (NASDAQ:BIIB)

Biogen stock rises after FDA approves high-dose Spinraza for SMA; litifilimab data adds momentum amid mixed technical signals.

FDA Approves High Dose Regimen of SPINRAZA for People Living with SMA

/PRNewswire/ -- Cure SMA, the leading nonprofit organization supporting those impacted by spinal muscular atrophy (SMA), celebrates that Biogen today announced...

FDA Approves High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy, Reflecting Progress Made Possible Through Decades of MDA Supported Research

MDA’s research funding for Dr. Adrian Krainer’s research led to the groundbreaking discovery of SPINRAZA®.

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA will be available in the United States…

FDA approves high-dose Spinraza regimen as treatment for SMA

The FDA has approved a high-dose regimen of Spinraza (nusinersen) as a treatment for spinal muscular atrophy (SMA).

US FDA approves higher dose of Biogen’s genetic disorder drug - Regional Media News

March 30 (Reuters) - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, the company said on Monday, offering patients a potentially more effective option. The regulator had declined to approve the company's application last year, seeking updated technical information. The therapy, Spinraza, is approved in the U.S. for spinal muscular atrop…